| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 分部间抵销(元) | -55,448,800.00 | - | - | - | -48,854,400.00 |
| 输液产品(元) | 1,786,359,600.00 | - | - | - | 1,353,419,900.00 |
| 制剂药品(不含大输液)(元) | 4,198,180,000.00 | - | - | - | 3,606,259,000.00 |
| 慢病业务平台(元) | - | 3,134,297,321.07 | 1,560,998,791.17 | 3,151,635,215.81 | - |
| 输液业务平台(元) | - | 3,176,919,995.01 | 1,669,180,896.73 | 2,596,961,100.72 | - |
| 专科业务平台(元) | - | 1,520,165,287.05 | 746,360,915.99 | 1,415,155,901.40 | - |
| 原料药(元) | - | 1,257,466,050.90 | 696,035,664.70 | - | - |
| 其他(元) | - | 1,024,908,046.44 | 499,436,900.09 | 2,180,183,624.84 | - |
| 营业成本(元) | |||||
| 分部间抵销(元) | -54,843,000.00 | - | - | - | -48,047,700.00 |
| 输液产品(元) | 819,246,300.00 | - | - | - | 728,254,400.00 |
| 制剂药品(不含大输液)(元) | 1,696,471,700.00 | - | - | - | 1,452,839,200.00 |
| 慢病业务平台(元) | - | 715,189,783.98 | 329,399,453.03 | 668,074,053.63 | - |
| 输液业务平台(元) | - | 1,470,376,956.78 | 781,577,359.27 | 1,343,081,490.46 | - |
| 专科业务平台(元) | - | 529,039,713.61 | 245,339,214.92 | 439,810,828.18 | - |
| 原料药(元) | - | 1,119,471,642.58 | 602,966,259.20 | - | - |
| 其他(元) | - | 697,661,767.72 | 310,943,325.86 | 1,721,526,869.09 | - |
| 毛利(元) | |||||
| 分部间抵销(元) | -605,800.00 | - | - | - | -806,700.00 |
| 输液产品(元) | 967,113,300.00 | - | - | - | 625,165,500.00 |
| 制剂药品(不含大输液)(元) | 2,501,708,300.00 | - | - | - | 2,153,419,800.00 |
| 慢病业务平台(元) | - | 2,419,107,537.09 | 1,231,599,338.14 | 2,483,561,162.18 | - |
| 输液业务平台(元) | - | 1,706,543,038.23 | 887,603,537.46 | 1,253,879,610.26 | - |
| 专科业务平台(元) | - | 991,125,573.44 | 501,021,701.07 | 975,345,073.22 | - |
| 原料药(元) | - | 137,994,408.32 | 93,069,405.50 | - | - |
| 其他(元) | - | 327,246,278.72 | 188,493,574.23 | 458,656,755.75 | - |
| 毛利率(%) | |||||
| 分部间抵销(%) | 1.09 | - | - | - | 1.65 |
| 输液产品(%) | 54.14 | - | - | - | 46.19 |
| 制剂药品(不含大输液)(%) | 59.59 | - | - | - | 59.71 |
| 慢病业务平台(%) | - | 77.18 | 78.90 | 78.80 | - |
| 输液业务平台(%) | - | 53.72 | 53.18 | 48.28 | - |
| 专科业务平台(%) | - | 65.20 | 67.13 | 68.92 | - |
| 原料药(%) | - | 10.97 | 13.37 | - | - |
| 其他(%) | - | 31.93 | 37.74 | 21.04 | - |
| 收入构成(%) | |||||
| 分部间抵销(%) | -0.94 | - | - | - | -0.99 |
| 输液产品(%) | 30.13 | - | - | - | 27.56 |
| 制剂药品(不含大输液)(%) | 70.81 | - | - | - | 73.43 |
| 慢病业务平台(%) | - | 30.99 | 30.18 | 33.73 | - |
| 输液业务平台(%) | - | 31.41 | 32.27 | 27.79 | - |
| 专科业务平台(%) | - | 15.03 | 14.43 | 15.15 | - |
| 原料药(%) | - | 12.43 | 13.46 | - | - |
| 其他(%) | - | 10.13 | 9.66 | 23.33 | - |
| 毛利构成(%) | |||||
| 分部间抵销(%) | -0.02 | - | - | - | -0.03 |
| 输液产品(%) | 27.89 | - | - | - | 22.51 |
| 制剂药品(不含大输液)(%) | 72.13 | - | - | - | 77.52 |
| 慢病业务平台(%) | - | 43.34 | 42.44 | 48.02 | - |
| 输液业务平台(%) | - | 30.57 | 30.59 | 24.25 | - |
| 专科业务平台(%) | - | 17.76 | 17.27 | 18.86 | - |
| 原料药(%) | - | 2.47 | 3.21 | - | - |
| 其他(%) | - | 5.86 | 6.50 | 8.87 | - |